Dfn-15
Spinal Muscular Atrophy (SMA)
Hugh McMillanPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 89/ 100
Competitive context
22 Active assets in the Spinal Muscular Atrophy (SMA) cohort.
View all 40 →
Same molecule, other indications
Dfn-15 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →